Neutropenic Toxic Epidermal Necrolysis Due to Sulfonamide Use

Year 2019, Volume: 1 Issue: 3, 117 - 120, 28.11.2019

Handan Bilen , Haticetül Kübra Sarı

Abstract

Toxic Epidermal Necrolysis (TEN), which has high
mortality and morbidity rates, often develops after medication. Clinically, at
least 30% of the mucous membranes and skin are involved. Neutropenia is very
rare in TEN cases and is directly related to mortality. We wanted to share a case
diagnosed with TEN, caused by trimethoprim/sulfamethoxazole, who developed
neutropenia during follow-up and was discharged with full recovery with early
diagnosis and effective treatment.

Keywords

toxic epidermal necrolysis, neutropenia, cotrimoxazole

References

• 1. Gleckman, R., N. Blagg, and D.W. Joubert. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy, 1981. 1(1): p. 14-20.
• 2. Dodiuk-Gad, R.P., et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol, 2015. 16(6): p. 475-93.
• 3. Roujeau, J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol, 1994. 102(6): p. 28S-30S.
• 4. Duncan, K.O., R.E. Tigelaar, and J.L. Bolognia, Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. J Am Acad Dermatol, 1999. 40(3): p. 493-6.
• 5. Roujeau, J.C. and R.S. Stern. Severe adverse cutaneous reactions to drugs. N Engl J Med, 1994. 331(19): p. 1272-85.
• 6. Mockenhaupt, M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges, 2009. 7(2): p. 142-60; quiz 161-2.
• 7. Shear, N.H., et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med, 1986. 105(2): p. 179-84.
• 8. Revuz, J., et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol, 1987. 123(9): p. 1160-5.
• 9. Gueudry, J., et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol, 2009. 145(2): p. 157-62.
• 10. Meneux, E., et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol, 1998. 91(2): p. 283-7.
• 11. Fernando, S.L. The management of toxic epidermal necrolysis. Australas J Dermatol, 2012. 53(3): p. 165-71.
• 12. Kirchhof, M.G., et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol, 2014. 71(5): p. 941-7.
• 13. Paradisi, A., et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol, 2014. 71(2): p. 278-83.